Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Northcoast Research Downgrades Shake Shack to Neutral

Northcoast Research analyst Jim Sanderson downgrades Shake Shack (NYSE:SHAK) from Buy to Neutral.

byBenzinga Newsdesk

November 8, 2021

1 minute read

Northcoast Research analyst Jim Sanderson downgrades Shake Shack (NYSE:SHAK) from Buy to Neutral.

MKM Partners Upgrades Continental Resources to Buy, Raises Price Target to $56

By Benzinga Newsdesk

Today, 11:37 AM

MKM Partners analyst John Gerdes upgrades Continental Resources (NYSE:CLR) from Neutral to Buy and raises the price target from $54 to $56.

CLR

News

Radius Health Gives Update On Abaloparatide Transdermal System

By Benzinga Newsdesk

Today, 11:37 AM

Radius Health Update on Abaloparatide Transdermal System Company ascertained regulatory clarity for possible forward progression of abalo-TDS Additional and successful clinical trial would be required to advance

RDUS

Tegna’s Debt Overview

By Benzinga Insights

Today, 11:37 AM

Over the past three months, shares of Tegna (NYSE:TGNA) increased by 7.84%. Before having a look at the importance of debt, let us look at how much debt Tegna has.

TGNA

FDA Advisory Committee Gives Thumbs Up To TransMedics’ OCS Liver System

By Vandana Singh

Today, 11:37 AM

The Gastroenterology and Urology Devices Panel of the FDA’s Medical Devices Advisory Committee has issued a favorable vote to…

TMDX

Northcoast Research Downgrades Shake Shack to Neutral

Related Posts

MKM Partners Upgrades Continental Resources to Buy, Raises Price Target to $56

Radius Health Gives Update On Abaloparatide Transdermal System

Tegna’s Debt Overview

FDA Advisory Committee Gives Thumbs Up To TransMedics’ OCS Liver System